Clinical Trial Detail

NCT ID NCT03923270
Title Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

lung small cell carcinoma

Therapies

Durvalumab + Tremelimumab

Durvalumab

Durvalumab + Olaparib

Age Groups: senior adult

No variant requirements are available.